The present invention relates to compounds having pharmacological activity in the treatment of vascular cholesterol accumulation, plasma low-density lipoproteins (LDL) abnormal aggregation and/or inhibition or reduction of the formation of VSMC foam cells, processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy and/or prophylaxis of conditions wherein decrease of vascular cholesterol accumulation, inhibition of LDL aggregation, inhibition or reduction of the formation of VSMC foam cells and/or prevention of aggregated LDL (agLDL) internalization is useful such as atherosclerosis, coronary artery disease, stroke, peripheral artery disease, angina pectoris, thrombosis, hyperlipidemia, hyperlipoproteinemia type II, familial hypercholesterolemia, familial combined hyperlipidemia, type II diabetes, hypothyroidism, Cushing's syndrome and obesity.
本发明涉及在治疗血管
胆固醇积聚、血浆低密度脂蛋白(LDL)异常聚集和/或抑制或减少VSMC泡沫细胞形成方面具有药理活性的化合物、制备它们的工艺、包含它们的药物组合物,以及它们在治疗和/或预防减少血管
胆固醇积聚的疾病中的用途、如动脉粥样硬化、冠状动脉疾病、中风、外周动脉疾病、心绞痛、血栓形成、高脂血症、II 型高脂蛋白血症、家族性高
胆固醇血症、家族性合并高脂血症、II 型糖尿病、甲状腺功能减退症、库欣综合征和肥胖症。